Business Wire

Zilch Accelerates Growth and Halves Costs with Taktile’s Next-Generation Decision Platform

6.11.2024 10:00:00 EET | Business Wire | Press release

Share

Zilch, the fintech payments innovator of the world’s first ad-subsidized payments network (ASPN), has revolutionized its underwriting infrastructure, achieving savings by reducing provider and usage costs by over half by transitioning to Taktile, a cutting-edge decisioning platform. This strategic shift not only enhances Zilch’s operational efficiency but also supports the company’s sustained growth in the highly competitive financial technology sector.

Pioneering Change in Consumer Payments

As a frontrunner in consumer payments, Zilch’s vision is to eliminate the high cost of consumer credit, for good. It empowers consumers to make purchases anywhere, anytime, without the burden of falling into revolving debt traps that cost consumers $150bn in interest and fees in just the US and UK alone. Having saved its 4m+ customers over $600m since launch in 2020 and as the first regulated credit product of its kind in the BNPL industry, Zilch’s ambitious target is to reduce that $150bn to zero, to Zilch. To continue delivering on this vision and recognizing the rapid advances in decisioning software, Zilch saw the need to modernize its credit underwriting processes to provide greater resilience, flexibility, and scalability.

The Solution: Taktile’s Transformative Platform

Under the leadership of Zilch’s Chief Risk Officer, Des Mcnamara, Chanuka Perera, Head of Credit Risk at Zilch, led the search for a platform that could align with Zilch’s ambitious growth plans. After an extensive evaluation of several automated decisioning tools, Taktile emerged as the clear choice, offering the flexibility and innovation that Zilch needed.

“Taktile’s platform has empowered our teams to take control of our automated underwriting processes, allowing us to build, test, and optimize decisions with unprecedented speed and independence,” said Chanuka Perera. “This shift has not only streamlined our operations but has also resulted in significant cost savings, freeing up resources for further innovation.”

Seamless Integration and Empowerment

The transition to Taktile was swift and seamless, with Zilch completing the migration and going live with the new system in just four weeks. Taktile’s intuitive user interface, featuring pre-built “Nodes,” enables Zilch’s subject matter experts to create and refine underwriting decisions without the need for external support or technical expertise.

Taktile’s Data Marketplace, which includes a vast library of pre-built data integrations, further simplified Zilch’s operations by providing easy access to essential data providers. This self-serve capability has empowered Zilch’s credit and risk teams to rapidly develop, test, and optimize decision flows, significantly reducing reliance on external consultants.

A Strategic Move for Long-Term Success

The impact of adopting Taktile extends beyond immediate cost savings. With a flexible, scalable platform, Zilch is now more robustly equipped to navigate the complexities of its rapidly scaling global operations and respond to evolving market demands.

“We see our partnership with Taktile as a notable driver of our success to date and one that’ll grow stronger. By reducing costs and increasing agility, we are now more prepared than ever to meet the needs of our customers and expand our reach,” added Perera.

About Zilch

Zilch’s vision is to eliminate the high cost of consumer credit. For good.

Zilch is a multi-award-winning pioneer of the world’s first direct-to-consumer, ad-subsidised payments network (ASPN). Leveraging its unique, vertically integrated, first-party-data business model, Zilch sets itself apart from the incumbent fintech industry with a profitable global revenue source, bringing unrivalled value to customers and marketers alike. Today, Zilch is revolutionising the $50 trillion advertising and payments industries by merging the very best of debit, credit, and savings.

Co-founded by Philip Belamant, Sean O’Connor, and Serge Belamant, Zilch provides millions of customers the freedom to go anywhere in the world (online or offline) and, when they pay, earn up to 5% cashback & rewards on debit payments (‘Pay Now’) or spread interest-free credit repayments over six weeks or three months. In the process, Zilch helps customers build their credit profiles with the major credit agencies. Within 44 months since its launch in 2020, Zilch amassed more than 4 million registered customers.

In September 2024, four years after its public launch in 2020, Zilch announced that in July 2024, it had achieved first-month profitability in record time while surpassing $130 million in revenue run rate, keeping pace with European fintech giants like Revolut, Starling Bank, and Monzo.

In 2023, Zilch launched its proprietary ASPN service, which allows merchants worldwide instant connection with Zilch’s first-party-data, closed-loop network of millions of high-intent customers, while offering customers personalised savings, deals, and discounts codified to their habitual daily spend.

In January 2023, Zilch struck a ground-breaking reporting agreement with the UK’s prime credit reference agencies, transforming the UK lending ecosystem by enabling all adults to build their credit records using interest-free credit rather than high-cost revolving credit products.

Since April 2020, Zilch has been regulated by the Financial Conduct Authority (FCA), obtaining a consumer credit licence through the Regulatory Sandbox Programme.

Driven by innovation and a commitment to excellence, Zilch is setting new benchmarks in the industry to create a more inclusive and efficient ecosystem, empowering millions of users to budget and manage their financial lives more effectively and transparently.

For more information, visit: www.zilch.com.

About Taktile

Taktile is a next-generation decision platform that empowers subject matter experts to build, monitor, and optimize automated risk decisions across the entire customer lifecycle—from credit underwriting and onboarding & KYC/KYB to transaction monitoring and collections. With its low-code UI and best-in-class marketplace of third-party data integrations, Taktile enables credit, fraud, and risk teams to reduce reliance on engineering, adapt quickly to market changes, and ultimately drive growth while lowering operational costs.

View source version on businesswire.com: https://www.businesswire.com/news/home/20241106270583/en/

Contacts

Zilch – Ryan Mendy, Chief Communications Officer: Comms@zilch.com
For any Press & Media enquiries, please contact: zilch@hawthornadvisors.com

Taktile – Ashley Baird, ashley.baird@taktile.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

www.businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Galderma Receives U.S. FDA Approval for Differin ® Epiduo ® Acne Gel Prescription-to-OTC Switch22.5.2026 19:25:00 EEST | Press release

Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) use in ages 12 years and older, marking a significant Prescription-to-OTC transition in acne care. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522074280/en/ The U.S. FDA approves Differin® Epiduo® Acne Gel Prescription-to-OTC switch This milestone represents yet another example of Galderma’s unique Integrated Dermatology strategy, demonstrating how proven innovations from its Therapeutic Dermatology portfolio can further strengthen its Dermatological Skincare offerings. The Prescription‑to‑OTC transition highlights Galderma’s scale and expertise in successfully commercializing dermatology innovations across the full spectrum of acne care. With the appro

Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 17:18:00 EEST | Press release

Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522186975/en/ Adam Plich, CEO and Co-Founder of Avanzanite Bioscience. “Thalassaemia is a complex, chronic and multisystem disease characterised by anaemia, ineffective erythropoiesis and haemo

ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 15:30:00 EEST | Press release

OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future

Enhertu ® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 15:00:00 EEST | Press release

Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority

Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 14:45:00 EEST | Press release

Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, signalling a shift in health systems from late-stage treatment to earlier intervention. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522587414/en/ Selected from 393 submissions across 68 countries, the winning teams were recognised through the inaugural ‘Future Health Challenge 2026: Building Anticipatory Health Systems through Population Sensing’, delivered by Future Health – A Global Initiative by Abu Dhabi in collaboration with MIT Solve. Health systems globally are facing rising costs and persistent delays in diagnosis, with many conditions still identified only after symptoms become severe. At the sam

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye